Clinical trials: ARDS Associated With COVID-19
COVID-19, ARDS
Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS
To evaluate the safety and efficacy of intravenous administration of bone marrow derived extracellular vesicles, ExoFlo, versus placebo as treatment for moderate-to-severe Acute Respiratory Distress Syndrome (ARDS) in patients…
- Trial name
- EXIT-COVID19 (NCT04493242)
- Testing
- ExoFlo, Intravenous normal saline
- Where
- 6 sites in United States
- Volunteers
- 102 people
- Sponsor
- Direct Biologics, LLC
Coronavirus Infection, Pneumonia, Viral
COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III
The Severe Acute Respiratory Syndrome COronaVirus 2 (SARS-CoV2) is a new and recognized infectious disease of the respiratory tract. Most cases are mild or asymptomatic.
- Conditions
- Coronavirus Infection, Pneumonia, Viral, Acute Respiratory Distress Syndrome
- Trial name
- CoDEX (NCT04327401)
- Testing
- Dexamethasone
- Where
- 21 sites in Brazil
- Volunteers
- 299 people
- Sponsor
- Hospital Sirio-Libanes
COVID-19, Acute Respiratory Distress Syndrome
Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS
A phase1/2, open label, dose escalation, safety and early efficacy study of CAStem for the treatment of severe COVID-19 associated with or without ARDS.
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Virus; Pneumonia, Acute Lung Injury
- Trial name
- NCT04331613
- Testing
- CAStem
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Chinese Academy of Sciences
Covid19
ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure.
- Trial name
- TESICO (NCT04843761)
- Testing
- Remdesivir, Aviptadil, Corticosteroid
- Where
- 40 sites in United States
- Volunteers
- 473 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with…
- Conditions
- COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04565665
- Testing
- Best Practice, Mesenchymal Stem Cell
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
COVID, Corona Virus Infection
Intensive Care Associated Complications and Outcome of Acute Respiratory Distress Syndrome Due to COVID-19
COVID-19 patients with a severely symptomatic progression with development of an Acute respiratory distress syndrome (ARDS) due to SARS-CoV-2 need prolonged intensive care treatment involving pharmacological immobilization…
- Conditions
- COVID, Corona Virus Infection, Sars-CoV2
- Trial name
- NCT04397172
- Testing
- Study Arm
- Where
- Switzerland
- Volunteers
- 48 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially…
- Trial name
- regARDS (NCT05027815)
- Testing
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jeffrey Bluestone
Covid19, ARDS, Human
MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome
Considering the potential of mesenchymal stromal cells (MSCs) in the treatment of lung injuries by COVID-19, this pilot clinical trial evaluates the safety and potential efficacy of the cell therapy, administered intravenously…
- Trial name
- NCT04525378
- Testing
- Mesenchymal stromal cell-based therapy
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- D'Or Institute for Research and Education
Respiratory Distress Syndrome
Place of ECMO in the Management of Severe Refractory ARDS Associated With Covid-19
Describe COVID-19 patients who are receiving ECMO-VV respiratory replacement and what happens to them.
- Trial name
- ECMO-COVID-19 (NCT04343404)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
COVID-19 Pneumonia, COVID-19
Safety of Nebulized Combination Therapy BromAc® in COVID-19 Respiratory Disease
COVID-19 has multiple facets including cytokine storm, thromboembolism and gelatinous secretions. It is known that oxygen exchange is the main problem in patients with COVID-19 and hypoxia is one of the most serious, in which…
- Conditions
- COVID-19 Pneumonia, COVID-19, Ventilator Associated Pneumonia, COVID-19 Acute Respiratory Distress Syndrome
- Trial name
- NCT05258682
- Testing
- Bromelains, Acetylcysteine
- Volunteers
- 30 people
- Sponsor
- Mucpharm Pty Ltd
ARDS Associated With COVID-19
Flow Controlled Ventilation in ARDS Associated With COVID-19
The pandemic of a newly upcoming viral disease which is associated with COVID-19 puts the whole world's health system under pressure.
- Trial name
- NCT04399317
- Testing
- Flow controlled ventilation (Evone-ventilator)
- Where
- Qatar
- Volunteers
- 20 people
- Sponsor
- Hamad Medical Corporation
COVID-19 Pneumonia, Bromelains Adverse Reaction
Nebulised BromAc in Healthy Volunteers
COVID-19 is a disease that has multiple facets including an inflammatory storm, it promotes blood clotting and causes kidney damage, mucinous secretions in the lung are of great importance to outcome.
- Conditions
- COVID-19 Pneumonia, Bromelains Adverse Reaction, Acetylcysteine Adverse Reaction, Mucus; Plug
- Trial name
- NCT05220605
- Testing
- BromAc
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Mucpharm Pty Ltd